よむ、つかう、まなぶ。
07 参考資料２－１ 帯状疱疹ワクチン ファクトシート (51 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_36248.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第21回 11／9）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R,
Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW,
Silber JL; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and
postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-84.
104. Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, Keay S, Stek
JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J. Efficacy, safety,
and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012;
54: 922-8.
105. Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in
older adults and the risk of subsequent herpes zoster disease. JAMA 2011; 305: 160-6.
106. Leroux-Roels
I, Leroux-Roels
G, Clement
F, Vandepapelière
P, Vassilev
V, Ledent E, Heineman TC. A phase 1/2 clinical trial evaluating safety and immunogenicity
of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J
Infect Dis 2012; 206: 1280-90.
107. Cunningham AL. The herpes zoster subunit vaccine. Expert Opin Biol Ther 2016; 16:
265-71.
108. Berkowitz EM, Moyle G, Stellbrink HJ, Schürmann D, Kegg S, Stoll M, El Idrissi
M, Oostvogels
L, Heineman
TC; Zoster-015
HZ/su Study Group.
Safety
and
immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected
adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis 2015; 211: 1279-87.
109. Lal H, Zahaf T, Heineman TC. Safety and immunogenicity of an AS01-adjuvanted varicella
zoster virus subunit candidate vaccine (HZ/su): a phase-I, open-label study in Japanese
adults. Human Vaccin Immunother 2013; 9: 1425-9.
110. Sarkadi J, Jankovics M, Fodor K, Kis Z, Takacs M, Visontai I, Jankovics I, Gonczol E.
High-level cellular and humoral immune responses in Guinea pigs immunized
intradermally with a heat-inactivated varicella-zoster virus vaccine. Clin Vaccine Immunol
2015; 22: 570-7.
111. Levine MJ, Ellison MC, Zerbe GO, Barber D, Chan C, Stinson D, Jones M, Hayward AR.
Comparison of a live attenuated and an inactivated varicella vaccine to boost the
varicella-specific immune response in seropositive people 55 years of age and older.
Vaccine 2000; 18: 2915-20.
112. Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, Betts R, Gelb
L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman
CA, Marques A, Toney J, Boardman K, Su SC, Li X, Chan IS, Parrino J, Annunziato
P, Oxman MN; Shingles Prevention Study Group. Long-term persistence of zoster vaccine
efficacy. Clin Infect Dis 2015; 60: 900-9.
46
Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW,
Silber JL; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and
postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-84.
104. Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, Keay S, Stek
JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J. Efficacy, safety,
and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012;
54: 922-8.
105. Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in
older adults and the risk of subsequent herpes zoster disease. JAMA 2011; 305: 160-6.
106. Leroux-Roels
I, Leroux-Roels
G, Clement
F, Vandepapelière
P, Vassilev
V, Ledent E, Heineman TC. A phase 1/2 clinical trial evaluating safety and immunogenicity
of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J
Infect Dis 2012; 206: 1280-90.
107. Cunningham AL. The herpes zoster subunit vaccine. Expert Opin Biol Ther 2016; 16:
265-71.
108. Berkowitz EM, Moyle G, Stellbrink HJ, Schürmann D, Kegg S, Stoll M, El Idrissi
M, Oostvogels
L, Heineman
TC; Zoster-015
HZ/su Study Group.
Safety
and
immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected
adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis 2015; 211: 1279-87.
109. Lal H, Zahaf T, Heineman TC. Safety and immunogenicity of an AS01-adjuvanted varicella
zoster virus subunit candidate vaccine (HZ/su): a phase-I, open-label study in Japanese
adults. Human Vaccin Immunother 2013; 9: 1425-9.
110. Sarkadi J, Jankovics M, Fodor K, Kis Z, Takacs M, Visontai I, Jankovics I, Gonczol E.
High-level cellular and humoral immune responses in Guinea pigs immunized
intradermally with a heat-inactivated varicella-zoster virus vaccine. Clin Vaccine Immunol
2015; 22: 570-7.
111. Levine MJ, Ellison MC, Zerbe GO, Barber D, Chan C, Stinson D, Jones M, Hayward AR.
Comparison of a live attenuated and an inactivated varicella vaccine to boost the
varicella-specific immune response in seropositive people 55 years of age and older.
Vaccine 2000; 18: 2915-20.
112. Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, Betts R, Gelb
L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman
CA, Marques A, Toney J, Boardman K, Su SC, Li X, Chan IS, Parrino J, Annunziato
P, Oxman MN; Shingles Prevention Study Group. Long-term persistence of zoster vaccine
efficacy. Clin Infect Dis 2015; 60: 900-9.
46